Next 10 |
home / stock / fdmt / fdmt articles
4D Molecular Therapeutics Inc (NASDAQ:FDMT) announced an update on its 4D-710, an aerosolized genetic medicine for cystic fibrosis (CF) l...
Adverum Biotechnologies Inc (NASDAQ:ADVM) released preliminary safety and efficacy data from the ongoing LUNA Phase 2 trial in patients with w...
4D Molecular Therapeutics Inc (NASDAQ:FDMT) shares are trading lower by 11.7% to $28.33 Wednesday afternoon after the company announced an upsized ...
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Monday. The Dow traded down 0.53% to 38,4...
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected fi...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday. The Dow traded down 1.04% to 38,...
4D Molecular Therapeutics (NASDAQ:FDMT) shares are trading higher after the company released interim data from the Phase 2 PRISM clinical tria...
U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday. Shares of The Estée Lauder Companies Inc. (NYSE: EL) rose s...
U.S. stocks traded lower this morning, with the Dow Jones index falling around 150 points on Monday. Following the market opening Monday, the Dow t...
News, Short Squeeze, Breakout and More Instantly...
4D Molecular Therapeutics Inc. Company Name:
FDMT Stock Symbol:
NASDAQ Market:
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation 4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics...
2024-05-01 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-15 06:00:04 ET Gena Wang from Barclays issued a price target of $45.00 for FDMT on 2024-04-15 03:43:00. The adjusted price target was set to $45.00. At the time of the announcement, FDMT was trading at $26.35. The overall price target consensus is at $45.40 with ...